ICER finds GSK inhalers offer advantages over generics
The higher prices of two COPD inhalers from GSK that are targeted in the second round of government drug price negotiations are justified because of several advantages over generic competitors,...
View ArticleAfter Phase 3 depression setback, Neumora pauses two trials to make changes,...
Brain health biotech Neumora has stopped two of its Phase 3 trials in major depressive disorder to make adjustments after the first late-stage study unexpectedly failed at the beginning of this year....
View ArticleCallio emerges with $187M and ADCs from a decade-old Singapore biotech
Frazier Life Sciences and a cadre of well-known biotech investors are coming together for a new startup in the antibody-drug conjugates field, an area of cancer treatment R&D that has remained hot....
View ArticleNovo Nordisk signs $354M partnership with AI-guided biotech for ‘risky’ new...
Novo Nordisk has formed a $354 million research collaboration with Gensaic, the protein design company said on Monday, as the Danish pharma giant works to incubate new approaches in the metabolic ...
View ArticleGenentech's TNKase gets new approval; Sanofi gives up rights to oncology...
Plus, news about Nuvation Bio, Leqembi, IN8bio and Syros: Longtime clot-busting drug gets new approval: Roche and Genentech’s TNKase (tenecteplase) was approved Monday to treat acute ...
View ArticleNovartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront
Novartis is spending $55 million on global rights to Kyorin Pharmaceutical’s preclinical drug for inflammatory diseases in a deal that comes almost two decades after Novartis’ first pact with the...
View ArticleProtagonist, Takeda's profit sharing deal under spotlight after Phase 3 blood...
Protagonist Therapeutics reported a clean Phase 3 win on Monday for rusfertide — its rare blood disorder therapy — putting it on track for a fourth-quarter FDA submission. It also brings to the fore an...
View ArticleBiohaven’s ion channel drug fails pivotal bipolar mania study
Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s fourth-quarter earnings report. The Phase 2/3 study included an estimated 256...
View ArticlePliant calls it quits on Phase 2b IPF study
Pliant Therapeutics has officially discontinued a mid-stage study of its chronic lung disease treatment, less than a month after the trial's safety board recommended a halt. The South San Francisco...
View ArticleGSK, Amgen and AstraZeneca tout Phase 3 data in inflammatory nasal condition
GSK, Amgen and AstraZeneca released positive data supporting their rival drugs in a condition called chronic rhinosinusitis with nasal polyps, or CRSwNP. GSK’s depemokimab and Amgen and AstraZeneca’s...
View ArticleCerebral CEO David Mou has stepped down
The CEO of mental health startup Cerebral stepped down in December 2024, Endpoints News has learned. David Mou, who became CEO in May 2022, continues to serve in his previous post of chief medical...
View ArticleSofinnova Partners raises €1.2B to invest in life sciences
Sofinnova Partners has raised €1.2 billion ($1.26 billion) across its various investment strategies over the past year, the European life sciences investor said Tuesday morning, sharing its plans to...
View Article23andMe rejects CEO's second take-private offer
A special committee of 23andMe's board rejected CEO Anne Wojcicki's latest offer to take the company private. In her second attempt, Wojcicki — along with private equity firm New Mountain Capital —...
View ArticleNIH-backed research tries to use stem cells to restore the eye’s outer layer
Thirteen out of 14 people with eye damage experienced at least some improvements to their cornea after receiving a stem cell transplant in one eye in an early-stage study. The National Institutes of...
View ArticleUnitedHealthcare’s copay-only plan is booming, despite backlash over care...
Business is booming for UnitedHealthcare’s transparent-pricing health plan, as more companies consider offering alternative types of health insurance. The plan, called Surest, aims to fix a universal...
View ArticleBourla says Pfizer could transfer production to US to sidestep Trump's tariffs
Pfizer could “quickly” transfer operations from foreign sites to its US manufacturing network as a way to mitigate any impact from President Donald Trump’s tariffs, CEO Albert Bourla said. The pharma...
View ArticleTenaya raises about $53M; BeiGene’s PD-1 gets a first-line approval
Plus, news about Evotec and Osivax: Tenaya Therapeutics’ $52.5M public offering: The heart disease specialist intends to spend the proceeds from its offering of 75 million new shares to develop...
View ArticleAcelyrin rejects buyout offer from Tang’s Concentra, sticks to Alumis merger
The board of immunology biotech Acelyrin has rejected the buyout offer from Tang Capital's shell company Concentra Biosciences, clearing up any doubt about its pending merger with Alumis. Acelyrin's...
View ArticleSwiss biotech ends Phase 2 study in Alzheimer's shortly after Lilly and...
A small Swiss biotech has terminated a mid-stage test of a new type of oral drug for people with Alzheimer's disease, according to the federal clinical trials database. About eight months ago,...
View ArticlePepGen delays study for Duchenne drug as it awaits safety data from another...
PepGen is "temporarily pausing" a Phase 2 study of its exon 51 skipping drug for Duchenne muscular dystrophy, it said Tuesday. PepGen told Endpoints News via email that no patients have been enrolled...
View Article